Pharmstandard agrees key terms for acquiring Singapore drugmaker
Russia’s largest pharma company Pharmstandard (PHST RU) – with a market capitalization of around $2 billion - has announced key terms of a possible acquisition of 100% share capital of Singapore-based Bever Pharmaceutical, at a lower price than the previously mooted $630 million (The Pharma Letter July 10).
The total consideration for the acquisition of Bever is agreed at $590 million and will be funded by the combination of Pharmstandard’s shares and GDRs owned by Pharmstandard-Leksredstva OJSC in the amount of $542 million (price per share of 2,235.4 roubles and price per GDR of $20.76) and cash of $48 million, which may be financed from external sources.
This would be the second acquisition this year for Pharmstandard, which recently won government backing to takeover Petrovax Pharm, one of Russia’s leading vaccines producers that had been an target of USA-based Abbott Laboratories (TPL May 7).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze